breast cancer
Showing NaN - NaN of 215
Breast Cancer Trial in United States (ARV-471, ARV-471 in combination with palbociclib (IBRANCEĀ®))
Recruiting
- Breast Cancer
- ARV-471
- ARV-471 in combination with palbociclib (IBRANCEĀ®)
-
Palo Alto, California
- +16 more
Jan 30, 2023
Breast Cancer Trial in United States (Positron emission tomography (PET), Trastuzumab, Pertuzumab)
Active, not recruiting
- Breast Cancer
- Positron emission tomography (PET)
- +2 more
-
Birmingham, Alabama
- +9 more
Jan 20, 2023
Breast Tumors, Breast Cancer, HER2-positive Early Breast Cancer Trial in Worldwide (Trastuzumab Deruxtecan, Paclitaxel,
Recruiting
- Breast Neoplasms
- +2 more
- Trastuzumab Deruxtecan
- +5 more
-
Springdale, Arkansas
- +203 more
Jan 13, 2023
Multiparametric MRI asNon-Invasive Biomarker of Tumor
Recruiting
- Breast Cancer
- Triple-negative Breast Cancer
- Tempus assay
- +2 more
-
Nashville, TennesseeVanderbilt University Medical Center
Jan 10, 2023
Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Tumor Trial in Worldwide (G1T48, Palbociclib)
Completed
- Carcinoma, Ductal, Breast
- +6 more
-
Beverly Hills, California
- +14 more
Dec 14, 2022
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer Trial in United States (Pertuzumab+TRASTUZUMAB,
Recruiting
- HER2-positive Breast Cancer
- +5 more
- Pertuzumab+TRASTUZUMAB
- ADJUVANT ENDOCRINE THERAPY
-
Stamford, Connecticut
- +21 more
Dec 12, 2022
Breast Cancer Trial in Greece, Israel, United States (MammaPrint, BluePrint, and Full-Genome Testing)
Recruiting
- Breast Cancer
- MammaPrint, BluePrint, and Full-Genome Testing
-
Birmingham, Alabama
- +117 more
Dec 1, 2022
Breast Tumors, Breast Cancer, Breast Tumors Trial in United States (Standard Therapy, AMG 386 with or without Trastuzumab, AMG
Recruiting
- Breast Neoplasms
- +10 more
- Standard Therapy
- +32 more
-
Birmingham, Alabama
- +35 more
Nov 17, 2022
Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or
Active, not recruiting
- Melanoma
- +8 more
- Pegilodecakin
- +9 more
-
Los Angeles, California
- +9 more
Nov 15, 2022
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer Trial in United States (Niraparib, Dostarlimab)
Recruiting
- Stage I Breast Cancer
- +7 more
-
Baltimore, Maryland
- +6 more
Nov 11, 2022
Validation for Early Cancer Detection and Minimal Residual
Recruiting
- Brain Cancer
- +19 more
-
Duarte, California
- +6 more
Nov 10, 2022